Hepatitis B Virus (HBV) Therapeutics – 5EU Drug Forecast and Market Analysis to 2024

Date: 2016-08

Hepatitis B Virus (HBV) Therapeutics – 5EU Drug Forecast and Market Analysis to 2024


Chronic hepatitis B virus (HBV) infection is a serious chronic liver disease caused by the failure of viral clearance following acute HBV infection. Despite the availability of effective prophylactic vaccines, the disease remains a serious global health concern, with estimated over 350 million people worldwide currently living with this condition. In addition, patients with chronic hepatitis B are at a high risk of developing life-threatening complications including liver cirrhosis and hepatocellular carcinoma (HCC). In 2010, an estimated 786,000 HBV-related deaths occurred worldwide.

Available treatment for chronic hepatitis B focuses on viral suppression, and include oral nucleos(t)ide analogues (NAs) and pegylated interferon (PEG-IFN). The two therapy classes have distinctive strengths and weaknesses. Nevertheless, most patients are using long-term NA treatment, and suffer from issues such as high accumulated treatment cost and low compliance.

The chronic hepatitis B therapeutics market in the 5EU was valued at $532.1m in 2014. The anticipated arrival of novel branded therapies will be the strongest market driver in the 5EU during the forecast period. These therapies include Gilead鈥檚 TAF, a novel NA, along with three adjunct therapies, Arrowhead鈥檚 ARC-520, Gilead鈥檚 GS-9620, and Gilead鈥檚 GS-4774. GlobalData projects these four products will receive licensure in the 5EU in 2017, 2021, 2021, and 2023, respectively.

*This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase.


– Overview of HBV including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
– Detailed information on the key drugs in 5EU including product description, safety and efficacy profiles as well as a SWOT analysis.
– Sales forecast for the top drugs in 5EU from 2014-2024.
– Analysis of the impact of key events as well the drivers and restraints affecting 5EU HBV market.

Reasons to buy

– Understand and capitalize by identifying products that are most likely to ensure a robust return
– Stay ahead of the competition by understanding the changing competitive landscape for HBV.
– Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
– Make more informed business decisions from insightful and in-depth analysis of drug performance
– Obtain sales forecast for drugs from 2014-2024 in 5EU.


Contact With Us
Join templatemonster at google+
Customized Research
Request Sample